Evidence map›Paper›PMID 32832435›Full record

ArticleIndian dermatology online journal

Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) Task Force against Recalcitrant Tinea (ITART) Consensus on the Management of Glabrous Tinea (INTACT).

Madhu Rengasamy, Manjunath M Shenoy, Sunil Dogra, Neelakandhan Asokan, Ananta Khurana, Shital Poojary, Jyothi Jayaraman, Ameet R Valia, Kabir Sardana, Seetharam Kolalapudi and 7 more

Open access · diamondAbstract read
In one paragraph

Article in Indian dermatology online journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Terbinafine-Resistant Trichophyton Dermatophytosis in Australia.The Australasian journal of dermatology · 2026
    Article
  8. Article
  9. Global Emergence ofInfection and drug resistance · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 10 institutions in 1 country.

Madhu RengasamyDepartment of Dermatology, Venereology and Leprosy, Madras Medical College, Chennai, Tamil Nadu, India.
Manjunath M ShenoyDepartment of Dermatology, Venereology and Leprosy, Yenepoya Medical College, Deralakatte, Deralakatte, Mangalore, Karanataka, India.
Sunil DograDepartment of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Neelakandhan AsokanDepartment of Dermatology, Venereology and Leprosy, Government Medical College, Thrissur, Kerala, India.
Ananta KhuranaDepartment of Dermatology, Venereology and Leprosy, Dr Ram Manohar Lohia Hospital and Postgraduate Institute of Medical Education and Research, New Delhi, India.
Shital PoojaryDepartment of Dermatology, Venereology and Leprosy, K. J. Somaiya Hospital and Research Centre, Mumbai, Maharashtra, India.
Jyothi JayaramanDepartment of Dermatology, Venereology and Leprosy, Father Muller Medical College, Mangalore, Karnataka, India.
Ameet R ValiaConsultant Dermatologist, Harganga Mahal Annexe, Dadar TT, India.
Kabir SardanaDepartment of Dermatology, Venereology and Leprosy, Dr Ram Manohar Lohia Hospital and Postgraduate Institute of Medical Education and Research, New Delhi, India.
Seetharam KolalapudiHanuma Skin Center, Doctors Plaza, Kothapeta, Guntur, Andhra Pradesh, India.
Yogesh MarfatiaDepartment of Dermatology, Venereology and Leprosy, SBKS Medical College, Piparia, Vadodara, Gujarat, India.
P Narasimha RaoConsultant Dermatologist, Masab Tank, Hyderabad, Telangana, India.
Ramesh M BhatDepartment of Dermatology, Venereology and Leprosy, Father Muller Medical College, Mangalore, Karnataka, India.
Mahendra KuraDepartment of Dermatology, Venereology and Leprosy, Grant Medical College, Mumbai, Maharashtra, India.
Deepika PandhiDepartment of Dermatology, Venereology and Leprosy, University College of Medical Sciences and GTBH, New Delhi, India.
Shyamanta BaruaDepartment of Dermatology, Venereology and Leprosy, Assam Medical College and Hospital, Dibrugarh, Assam, India.
Vibhor KaushalConsultant Dermatologist, Dr. Kaushal's Skin Clinic, Agra, Uttar Pradesh, India.
Atal Bihari Vajpayee Institute of Medical Sciences and Dr. Ram Manohar Lohia Hospital · INFather Muller Medical College Hospital · INAssam Medical College · INGovernment Medical College · INGrant Medical College and Sir Jamshedjee Jeejeebhoy Group of Hospitals · INK. J. Somaiya Hospital & Research Centre · INMadras Medical College · INPost Graduate Institute of Medical Education and Research · INUniversity College of Medical Sciences · INYenepoya University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsDermatophytosis has always been a common superficial mycosis in India. However, the past 6-7 years have seen an unprecedented increase in the number of patients affected by recurrent, chronic, recalcitrant and steroid modified dermatophytosis involving the glabrous skin (tinea corporis, tinea cruris and tinea faciei). Importantly, there has been a notable decrease in clinical responsiveness to commonly used antifungals given in conventional doses and durations resulting in difficult-to-treat infections. Considering that scientific data on the management of the current epidemic of dermatophytosis in India are inadequate, the Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) Task force Against Recalcitrant Tinea (ITART) has formulated a consensus statement on the management of dermatophytosis in India.

methodsSeventeen dermatologists with a focussed interest in dermatophytosis participated in a Delphi consensus method, conducted in three rounds. They responded as either "agree" or "disagree" to 132 statements prepared by the lead experts and gave their comments. Consensus was defined as an agreement of 80% or higher concurrence. Statements on which there was no consensus were modified based on the comments and were then recirculated. The results were finally analysed in a face-to-face meeting and the responses were further evaluated. A draft of the consensus was circulated among the participants and modified based on their inputs.

resultsConsensus was achieved on 90 of the 132 statements. Direct microscopy using potassium hydroxide mount was recommended in case of diagnostic difficulty on clinical examination. Counselling of patients about strict adherence to general measures and compliance to treatment was strongly recommended as the key to successful management of dermatophytosis. A combination of systemic and topical antifungal drugs was recommended for the treatment of glabrous tinea in the current scenario. Topical corticosteroid use, whether used alone or in combination with other components, was strongly discouraged by all the experts. It was suggested that topical antifungals may be continued for 2 weeks beyond clinical resolution. Itraconazole and terbinafine were recommended to be used as the first line options in systemic therapy, whereas griseofulvin and fluconazole are alternatives. Terbinafine was agreed to be used as a first line systemic agent in treatment naïve and terbinafine naïve patients with glabrous tinea. Regular follow-up of patients to ensure compliance and monitoring of clinical response was recommended by the experts, both during treatment and for at least 4 weeks after apparent clinical cure. Longer duration of treatment was recommended for patients with chronic, recurrent and steroid modified dermatophytosis.

conclusionConsensus in the management of dermatophytosis is necessary in the face of conventional regimens proving ineffective and dearth of clinical trials re-evaluating the role of available antifungals in the wake of evolving epidemiology of the infection in the country. It needs to be backed by more research to provide the required level of evidence. It is hoped that this consensus statement improves the quality of care for patients with dermatophytosis, which has emerged as a huge public health problem, imposing considerable financial burden on the country.

Indexed as

Dermatophytosisglabrous tineaINTACTrecalcitrantrecommendationsresistancetask force

Identifiers

PMID32832435
PMCPMC7413465
OpenAlexW3080407494

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.